Shire to test its ADHD drug in 4 to 5-year olds in U.S.
Shire Plc SHP.L has agreed to a U.S. Food and Drug Administration request to study its stimulant Vyvanse in preschool children as concern rises over the diagnosis and treatment of attention deficit hyperactivity disorder, the drugmaker said on Thursday. A report last year by the Centers for Disease Control and Prevention found that the number of children diagnosed with ADHD increased 41 percent from 2003 to 2011 and that 6.4 million children, or 11 percent of those aged 4 to 17, have been diagnosed with that condition. Drugs treatments include Ritalin, Adderall and Vyvanse. Only Adderall, which is also made by Shire, is approved to treat children under the age of 6.
Medications/Drugs News Headlines – Yahoo! News
More From Around the Web
Check out these Articles
- One in five African children denied access to vaccines: report
- In Arizona, fighting the legacy of ‘America’s toughest sheriff’
- India’s drug stores plan protest against e-pharmacies
- Popular cholesterol drugs may make flu vaccine less effective
- Vilified for drug pricing, CEO Shkreli busted for securities fraud
- Man Beaten by Georgia Cops Speaks Out
- Hepatitis C linked to higher risk of head and neck cancers
- Indonesia’s battle to bring healthcare to the masses
- Turkey aims to bolster local drug production, minister says
- Embattled drugmaker Valeant cuts ties to Philidor
- U.S FDA issues draft guidance for abuse-deterrent opioid generics
- Pennsylvania governor stays execution of killer, citing shortage of lethal ...
- Gain from adding Roche’s Avastin to immune drug unclear